Close Menu

NEW YORK – Natera said on Monday that it has sued ArcherDx, alleging infringement of a recently issued patent covering target amplification.

In its complaint, filed with the US District Court of Delaware, San Carlos, California-based Natera said that ArcherDx, based in Boulder, Colorado, infringes its US Patent No. 10,538,814 titled "Methods for Simultaneous Amplification of Target Loci." The patent, issued on Jan. 21, covers methods that use multiplex PCR to amplify several nucleic acid regions in the same reaction for sequencing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.